forked from NBCLab/NBCLab.github.io
-
Notifications
You must be signed in to change notification settings - Fork 4
Commit
This commit does not belong to any branch on this repository, and may belong to a fork outside of the repository.
Created test of 2024-02-01-conti-gabriele.md
- Loading branch information
1 parent
5cd2f30
commit 3cebba2
Showing
1 changed file
with
23 additions
and
0 deletions.
There are no files selected for viewing
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
Original file line number | Diff line number | Diff line change |
---|---|---|
@@ -0,0 +1,23 @@ | ||
--- | ||
layout: member | ||
title: Gabriele Conti | ||
position: Visiting PhD Student | ||
handle: gconti | ||
science_names: [G. Conti] | ||
image: conti-gabriele.jpg | ||
alumni: false | ||
country: [it] | ||
website: https://www.unibo.it/sitoweb/gabriele.conti12 | ||
|
||
# social | ||
email: [email protected] | ||
github: Gabriele-Conti | ||
orcid: 0000-0002-4623-043X | ||
linkedin: gabriele-conti-17713417a | ||
researchgate: Gabriele-Conti-3 | ||
twitter: ContiGabriele96 | ||
--- | ||
|
||
Gabriele holds BSc and MSc degrees in Biotechnology and Pharmaceutical Biotechnology, respectively, from the Alma Mater Studiorum University of Bologna (Italy), where he is currently a Ph.D. student in the Biotechnological Biocomputational Pharmaceutical Sciences program. His research focuses on the role of the human microbiome in various oncological diseases. Using biocomputational and biostatistical approaches to analyse next-generation sequencing (NGS) microbiome data, his work aims to develop personalised integrated intervention strategies for patients, with a particular focus on haematological malignancies in both adult and paediatric populations. | ||
|
||
During his visiting period at LUMC, Gabriele will focus on a paediatric cohort affected by various haematological malignancies to assess the role of the gut microbiome in allo-HSCT therapy. He will investigate the interaction of the gut microbiome with disease remission and progression, as well as side effects such as aGvHD and febrile neutropenia. |